Table 1. Deregulation of Jun family members in cancer.
| Observation | Tumour type | Method | Refs |
|---|---|---|---|
| JUN amplification and JUN overexpression | Liposarcoma | CGH, FISH, Real-time PCR and WB | 12 |
| Increased JUN expression | Non-small-cell lung cancer | IHC | 29,202 |
| Acute myeloid leukaemia | Microarray | 203 | |
| Colorectal neoplasm | IHC | 204 | |
| Pancreatic cancer | IHC | 205 | |
| Oral squamous cell carcinomas | IHC | 206 | |
| Increased levels of phosphorylated JUN | Astrocytoma | IHC | 207 |
| Invasive breast cancer | IHC | 146 | |
| Osteosarcoma | IHC | 208 | |
| Glioblastoma | IHC | 209 | |
| Melanoma | WB | 204 | |
| JUN and FOS overexpression | Prostate cancer | TMA | 175 |
| JUN and JUND overexpression | Breast cancer | TMA | 210 |
| JUN and JUNB overexpression | CD30+ lymphoma* | TMA and IHC | 174 |
| JUND overexpression | Primary cutaneous B cell lymphoma | IHC | 211 |
| JUNB and JUND overexpression | Colorectal adenocarcinoma | IHC and WB | 212 |
| Increased AP1 activity | Lung and bladder carcinoma | EMSA | 213 |
| Increased AP1 binding activity (FOS–JUNB) | Endometrial cancer | WB | 214 |
| Cervical cancer | EMSA and WB | 215 |
CGH, comparative genomic hybridization; EMSA, electrophoretic mobility shift assay; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; TMA, tumour microarray; WB, western blot.
*
Classic Hodgkin lymphoma, anaplastic large cell lymphoma, diffuse large B cell lymphoma.